Novel UL23 and UL30 substitutions in HSV1 and HSV2 viruses related to polymorphism or drug resistance.

J Giorgi, B Simon, G Destras, Q Semanas, C Ginevra, T Boyer, H Regue, G Billaud, S Ducastelle, F Ader, F Morfin, L Josset, E Frobert

Antiviral research 2023 Aug

filter terms:

Data on herpes simplex virus (HSV) polymorphism as well as acyclovir (ACV) and foscarnet (FOS) resistance mutations are not exhaustive and may hinder accurate diagnosis by next-generation sequencing (NGS). Here, we report novel UL23 and UL30 substitutions for HSV1 and HSV2 identified in immunocompromised patients treated for hematological malignancies during the last 6 years of HSV resistance surveillance at the University Hospital of Lyon. For HSV1, 35 novel UL23 substitutions and 52 novel UL30 substitutions were identified. For HSV2, 2 novel UL23 substitutions and 12 novel UL30 substitutions were identified. These results allow to complete the database of HSV1 and HSV2 substitutions, related either to polymorphism or to ACV and FOS resistance. Copyright © 2023. Published by Elsevier B.V.

Citation

J Giorgi, B Simon, G Destras, Q Semanas, C Ginevra, T Boyer, H Regue, G Billaud, S Ducastelle, F Ader, F Morfin, L Josset, E Frobert. Novel UL23 and UL30 substitutions in HSV1 and HSV2 viruses related to polymorphism or drug resistance. Antiviral research. 2023 Aug;216:105672